Table 3. Factors associated with incidence of DRMs.
| Variable | Mutation identified by DS (n = 18) | No mutations identified by DS (n = 11) | Overall(N = 29) | P |
|---|---|---|---|---|
| Regimen | ||||
| NVP+3TC+AZT | 7(38.9%) | 6(54.5%) | 13 | 0.941 |
| EFV+3TC+AZT | 8(44.4%) | 4(36.4%) | 12 | |
| LPV/r +3TC+AZT | 1(5.6%) | 1(9.1%) | 2 | |
| NVP+3TC+TDF | 1(5.6%) | 0 | 1 | |
| EFV+3TC+TDF | 1(5.6%) | 0 | 1 | |
| CD4 abs count(cells/ mm3) | ||||
| 0≤199 | 9(50.0%) | 6(54.5%) | 15 | 1.00 |
| ≥200 | 9(50.0%) | 5(45.5%) | 14 | |
| WHO Stage | ||||
| I | 9(50.0%) | 4(36.4%) | 13 | 0.901 |
| II | 4(22.2%) | 3(27.3%) | 7 | |
| III | 2(11.1%) | 2(18.2%) | 4 | |
| IV | 3(16.7%) | 2(18.2%) | 5 | |
| Route of transmission | ||||
| IDU | 5(27.8%) | 3(27.3%) | 8 | 0.503 |
| Heterosexual | 13(72.2%) | 7(63.6%) | 20 | |
| MSM | 0(0.0%) | 1(9.1%) | 1 | |
| Recently 7 days number of doses missed | <0.05 | |||
| 0 | 9 | 11 | 20 | |
| ≥1 | 9 | 0 | 9 |